Feasibility and advantage of adding (131)I-MIBG to (90)Y-DOTATOC for treatment of patients with advanced stage neuroendocrine tumors

BACKGROUND: Peptide receptor radionuclide therapy (PRRT) is an effective form of treatment for patients with metastatic neuroendocrine tumors (NETs). However, delivering sufficient radiation dose to the tumor to result in a high percentage of long-term tumor remissions remains challenging because of...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:EJNMMI Res
Main Authors: Bushnell, David L, Madsen, Mark T, O’cdorisio, Thomas, Menda, Yusuf, Muzahir, Saima, Ryan, Randi, O’dorisio, M Sue
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Berlin Heidelberg 2014
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4452658/
https://ncbi.nlm.nih.gov/pubmed/26116109
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13550-014-0038-2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados